MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic CancerGlobeNewsWire • Monday
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHNGlobeNewsWire • 10/23/26
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid TumorsGlobeNewsWire • 10/15/26
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 10/09/26
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/09/26
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial PositionGlobeNewsWire • 08/13/26
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific ProgramGlobeNewsWire • 08/11/26
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still ImportantSeeking Alpha • 07/27/26
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora PharmaceuticalsGlobeNewsWire • 07/02/26
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® ApprovalGlobeNewsWire • 06/22/26
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology ForumGlobeNewsWire • 05/14/26
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business TransformationGlobeNewsWire • 05/13/26
Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 05/05/26
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase AgreementGlobeNewsWire • 05/04/26
MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/12/26
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data DisclosuresGlobeNewsWire • 03/09/26